ArticleBMC cancer2024

Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial).

Mélanie Casile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.